Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RHOA | P61586 | 1/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.60 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.60 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | BCR | P11274 | 1/20 | 0.52 |
| ▸ | PRKCA | P17252 | 1/20 | 0.52 |
| ▸ | CDC25B | P30305 | 4/20 | 0.51 |
| ▸ | CDC25A | P30304 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CDC25C | P30307 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 3-Phenylamino Benzoic Acid SCHEMBL4345076 | 0.87 | RHOA (0.77) | RHOAAKR1C3AKR1C2KDM4ERAB9A | |
| SCHEMBL10838776 | 0.85 | ROCK1 (0.57) | RHOAKCNK3ABL1BCRMEN1 | |
| SCHEMBL24010242 | 0.83 | KCNK3 (0.75) | KDM4ERAB9ANPC1KCNK3MEN1 | |
| SCHEMBL24010214 | 0.82 | ABCG2 (0.59) | ABCG2KDM4ERAB9ANPC1MAPT | |
| SCHEMBL24006069 | 0.82 | NT5E (0.66) | KDM4ERAB9ANPC1L3MBTL1KCNK3 | |
| SCHEMBL30290758 | 0.82 | KCNK3 (0.69) | KDM4ERAB9ANPC1L3MBTL1KCNK3 | |
| SCHEMBL24010181 | 0.82 | KCNK3 (0.69) | KDM4ERAB9ANPC1L3MBTL1KCNK3 | |
| SCHEMBL24010655 | 0.81 | NPC1 (0.58) | RHOAAKR1C3AKR1C2RAB9ANPC1 | |
| SCHEMBL29818224 | 0.80 | ABL1 (0.54) | RHOAAKR1C3AKR1C2ABCG2RAB9A | |
| SCHEMBL11083807 | 0.80 | KCNK3 (0.82) | KDM4ETDP1RAB9AL3MBTL1KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4855308-A | Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents | WARNER-LAMBERT COMPANY (US) | 1989-08-08 | — | — | US | claimed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| WO-2021226458-A1 | AKT3 MODULATORS | GEORGIAMUNE LLC (US) | 2021-11-11 | — | — | WO | disclosed |
| US-4855308-A | Method of treating senile cognitive decline with N'-substituted aminopyridine adrenergic agents | WARNER-LAMBERT COMPANY (US) | 1989-08-08 | — | — | US | disclosed |
| US-4610991-A | Antihypertensive pyridylaminobenzamide compounds | STERLING DRUG INC. (US) | 1986-09-09 | — | — | US | disclosed |
| EP-0098951-A2 | Aminobenzamide derivatives and preparation thereof | STERLING DRUG INC. (US) | 1984-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | RHOA 1117/4885AKR1C3 1694/4885AKR1C2 2359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.